Abstract
Objective The objective of this study was to evaluate the efficacy of venlafaxine HCl in the symptomatic treatment of painful peripheral diabetic neuropathy (PPDN) among patients with type 2 diabetes mellitus (DM). Design This study was designed as a prospective, randomized, and controlled trial. Setting This study was conducted at the Dicle University Medical Faculty (Diyarbakir, Turkey). Patients Sixty type 2 DM outpatients (47 females and 13 males) with PPDN who had a minimum visual analog scale (VAS) score of 40 mm were enrolled in this study. Interventions Patients randomized to the treatment group ( n=30) received venlafaxine HCl, whereas those randomized to the control group ( n=30) received a combination of vitamins B 1and B 6 tablets. Measures Severity of pain was measured by VAS, Short-Form McGill Pain Questionnaire, and numerical analog scale scores at admission and at the second, fourth, and eighth weeks of the study. Polyneuropathy was supported by electromyelography. Outcome In the treatment group, severity of pain was measured as 70.0±13.0 in the VAS, as 24.9±6.2 in the Short-Form McGill Pain Questionnaire, and as 7.2±1.1 in the numerical analog scale. In the control group, it was measured as 73.0±8.0 in the VAS, as 26.8±6.2 in the Short-Form McGill Pain Questionnaire, and as 7.4±0.8 in the numerical analog scale ( P>.05). Results The most common form of PPDN was distal symmetrical sensorimotor polyneuropathy in both groups (46.8% vs. 50.0%). At the end of the study, there was a significant difference in severity of pain between the groups. In the treatment group, scores were 8.5±5.2 and 3.1±1.6 in the Short-Form McGill Pain Questionnaire and numerical analog scale, respectively; in the control group, these were 20.5±7.0 and 5.5±1.6, respectively ( P<.001). Conclusions Venlafaxine HCl is a safe and well-tolerable analgesic drug in the symptomatic treatment of PPDN; however, it has minimal adverse effects. It showed its efficacy markedly in the second week of therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
